SUBSTITUTED IMIDAZOPYRIMIDINES AND TRIAZOLOPYRIMIDINES
申请人:Siegel Stephan
公开号:US20100113441A1
公开(公告)日:2010-05-06
The invention relates to substituted imidazopyrimidines and triazolopyrimidines, to methods for the production thereof, and to the use of same for producing medicaments for the treatment and/or prophylaxis of diseases, especially haematological diseases, preferably leucopenia and neutropenia.
SUBSTITUTED IMIDAZO- AND TRIAZOLOPYRIMIDINES, IMIDAZO- AND PYRAZOLOPYRAZINES AND IMIDAZOTRIAZINES
申请人:Siegel Stephan
公开号:US20110144131A1
公开(公告)日:2011-06-16
The invention relates to substituted imidazo- and triazolopyrimidines, imidazo- and pyrazolopyrazines and imidazotriazines and processes for their preparation, and their use for the manufacture of medicaments for the treatment and/or prophylaxis of diseases, in particular of hematological disorders, preferably of leukopenias and neutropenias.
TRIAZOLOTRIAZINES AND TRIAZOLOPYRAZINES AND THEIR USE
申请人:Siegel Stephan
公开号:US20090258877A1
公开(公告)日:2009-10-15
The invention relates to substituted triazolotriazines and triazolopyrazines and to processes for their preparation, and also to their use for preparing medicaments for the treatment and/or prophylaxis of diseases, in particular haematologic disorders, preferably of leukopenias and neutropenias.
Imidazo-, pyrazolopyrazines and imidazotriazines and their use
申请人:Siegel Stephan
公开号:US08476267B2
公开(公告)日:2013-07-02
The invention relates to substituted imidazo-, pyrazolopyrazines and imidazotriazines and processes for their preparation, and their use for the manufacture of medicaments for the treatment and/or prophylaxis of diseases, in particular of hematological disorders, preferably of leukopenias and neutropenias.
Substituted pyridines, and use thereof as GSK3 inhibitors
申请人:Siegel Stephan
公开号:US08664246B2
公开(公告)日:2014-03-04
The invention relates to substituted pyridines and to processes for preparation thereof, and to the use thereof for production of medicaments for treatment and/or prophylaxis of diseases, especially of haematological disorders, preferably of leukopenia and neutropenia.